The global market for advanced renal cell carcinoma therapeutics is poised for substantial growth, projected to surge from its current valuation of USD 6.3 billion in 2022 to an impressive USD 10.66 billion by 2032. A recent analysis by Future Market Insights attributes this growth to an increasing prevalence of renal cell carcinoma cases worldwide, …